Folks should note the tiny float on this one, just under 3 million shares. And for a biotech, that is pretty much unknown so far, it has huge upside potential. I would hope the CEO can rally it to $10-$20 / share before he tries to raise serious phase 2-3 drug trial money, and if then land some partnerships or licenses early on it just fuel the rally fire. Or maybe a buy out of one of their technologies. Lots of good possibilities right now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.